BAL Fluid Biomarkers in Sarcoma
Prospective Study of Biomarkers Derived From Bronchoalveolar Lavage Fluid to Predict Outcomes in Soft-Tissue Sarcomas
University Health Network, Toronto
70 participants
Jan 29, 2025
INTERVENTIONAL
Conditions
Summary
This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.
Eligibility
Inclusion Criteria4
- Age ≥ 18 years
- Ability to understand and willingness to sign a written informed consent document
- Diagnosed with soft tissue sarcoma
- Undergoing resection of lung lesion as part of standard care
Exclusion Criteria1
- \. History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 2 years
Interventions
Routine bronchoscopy and standard of care metastasectomy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06815666